Skip to Content

Evotec SE ADR EVO

Morningstar Rating
$4.78 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger

Evotec is a drug discovery partnership firm that has a contract development and manufacturing organization, or CDMO, business, in addition to an innovative drug development program focused on collaboration with clients. The firm offers services across a variety of therapeutic areas and serves a diverse client base of large and midsize pharmaceutical and biotechnology companies. Following a recent period of investment that has weighed on returns, Evotec appears well positioned to mature and stabilize its business as its strategic growth initiatives materialize.

Price vs Fair Value

EVO is trading at a 128% premium.
Price
$4.78
Fair Value
$9.60
Uncertainty
High
1-Star Price
$95.52
5-Star Price
$6.98
Economic Moat
Bcqw
Capital Allocation
Yryjyzf

Bulls Say, Bears Say

Bulls

Evotec’s focus on building out its biologics manufacturing capacity makes it well positioned to capture heightened demand for biologics by biopharma companies.

Bears

Competitive market dynamics remain fierce, weighing on Evotec’s organic growth in the Shared R&D segment and putting pricing pressure on the firm’s more commoditized services.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EVO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$4.78
Day Range
$4.744.83
52-Week Range
$3.9413.49
Bid/Ask
$4.71 / $4.78
Market Cap
$1.69 Bil
Volume/Avg
27,692 / 150,373

Key Statistics

Price/Earnings (Normalized)
19.26
Price/Sales
2.00
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
5,055

Competitors

Valuation

Metric
EVO
CTLT
CRL
Price/Earnings (Normalized)
19.26102.0022.01
Price/Book Value
1.412.913.16
Price/Sales
2.002.552.80
Price/Cash Flow
46.5243.2815.08
Price/Earnings
EVO
CTLT
CRL

Financial Strength

Metric
EVO
CTLT
CRL
Quick Ratio
1.651.561.17
Current Ratio
1.862.511.75
Interest Coverage
−6.83−4.074.95
Quick Ratio
EVO
CTLT
CRL

Profitability

Metric
EVO
CTLT
CRL
Return on Assets (Normalized)
−4.21%−3.09%6.50%
Return on Equity (Normalized)
−8.08%−7.79%15.17%
Return on Invested Capital (Normalized)
−5.57%−0.96%9.55%
Return on Assets
EVO
CTLT
CRL
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
TzykbxgxwXlnr$83.1 Bil
Merck KGaA ADR
MKKGY
LtfvzhzcclGsrhwmv$73.3 Bil
Haleon PLC ADR
HLN
BknxnlfvLrsl$39.7 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
PwjjysvTlk$19.0 Bil
Viatris Inc
VTRS
LqkrhpnzGhcj$14.1 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
WhpvmnstCct$13.2 Bil
Catalent Inc
CTLT
LhpdqclcjDyzsp$10.5 Bil
Perrigo Co PLC
PRGO
GhhmpctmCdxk$3.8 Bil
Prestige Consumer Healthcare Inc
PBH
KrffrkrShyplmn$3.6 Bil
Curaleaf Holdings Inc
CURLF
XfcvjycqBfq$3.2 Bil

Sponsor Center